Seven grizzly (Ursus arctos; four male, three female) and three black (Ursus americanus; two male, one female) bears caught in culvert traps or leg snares were immobilized in northwestern Wyoming with carfentanil and xylazine at doses, respectively, of 0.011±0.001 and 0.12±0.01 mg/kg for grizzly bears and 0.014±0.002 and 0.15±0.04 mg/kg for black bears. These drugs were antagonized with 1 mg/ kg naltrexone and 2 mg/kg tolazoline. Induction and recovery times, respectively, were 4.3±0.5 and 7.1±0.8 min for grizzly bears and 5.2±0.4 and 9.1±2.2 min for black bears. Inductions were smooth and uneventful. Recoveries were characterized initially by increased respiration followed by raising of the head, which quickly led to a full recovery, with the bears recognizing and avoiding humans and moving away, maneuvering around obstacles. All bears experienced respiratory depression, which did not significantly improve with supplemental oxygen on the basis of pulse oximetry (P=0.56). Rectal temperatures were normothermic. Carfentanil-xylazine immobilization of bears provided significant advantages over other drug regimens, including small drug volumes, predictable inductions, quick and complete recoveries, and lower costs. On the basis of these data, both grizzly and black bears can be immobilized effectively with 0.01 mg/kg carfentanil and 0.1 mg/kg xylazine.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 49 • No. 3